|
1
|
Adams JC: Roles of fascin in cell adhesion
and motility. Curr Opin Cell Biol. 16:590–596. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kureishy N, Sapountzi V, Prag S, Anilkumar
N and Adams JC: Fascins, and their roles in cell structure and
function. Bioessays. 24:350–361. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Edwards RA and Bryan J: Fascins, a family
of actin bundling proteins. Cell Motil Cytoskeleton. 32:1–9. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grothey A, Hashizume R, Ji H, Tubb BE,
Patrick CW Jr, Yu D, Mooney EE and McCrea PD: C-erbB-2/HER-2
upregulates fascin, an actin-bundling protein associated with cell
motility, in human breast cancer cell lines. Oncogene.
19:4864–4875. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Grothey A, Hashizume R, Sahin AA and
McCrea PD: Fascin, an actin-bundling protein associated with cell
motility, is upregulated in hormone receptor negative breast
cancer. Br J Cancer. 83:870–873. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jawhari AU, Buda A, Jenkins M, Shehzad K,
Sarraf C, Noda M, Farthing MJ, Pignatelli M and Adams JC: Fascin,
an actin-bundling protein, modulates colonic epithelial cell
invasiveness and differentiation in vitro. Am J Pathol. 162:69–80.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hashimoto Y, Ito T, Inoue H, Okumura T,
Tanaka E, Tsunoda S, Higashiyama M, Watanabe G, Imamura M and
Shimada Y: Prognostic significance of fascin overexpression in
human esophageal squamous cell carcinoma. Clin Cancer Res.
11:2597–2605. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hwang JH, Smith CA, Salhia B and Rutka JT:
The role of fascin in the migration and invasiveness of malignant
glioma cells. Neoplasia. 10:149–159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hayashi Y, Osanai M and Lee GH: Fascin-1
expression correlates with repression of E-cadherin expression in
hepatocellular carcinoma cells and augments their invasiveness in
combination with matrix metalloproteinases. Cancer Sci.
102:1228–1235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Osanai M, Sawada N and Lee GH: Oncogenic
and cell survival properties of the retinoic acid metabolizing
enzyme, CYP26A1. Oncogene. 29:1135–1144. 2010. View Article : Google Scholar
|
|
11
|
Chang CL, Hong E, Lao-Sirieix P and
Fitzgerald RC: A novel role for the retinoic acid-catabolizing
enzyme CYP26A1 in Barrett’s associated adenocarcinoma. Oncogene.
27:2951–2960. 2008. View Article : Google Scholar
|
|
12
|
Shelton DN, Sandoval IT, Eisinger A,
Chidester S, Ratnayake A, Ireland CM and Jones DA: Up-regulation of
CYP26A1 in adenomatous polyposis coli-deficient vertebrates via a
WNT-dependent mechanism: Implications for intestinal cell
differentiation and colon tumor development. Cancer Res.
66:7571–7577. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brown GT, Cash BG, Blihoghe D, Johansson
P, Alnabulsi A and Murray GI: The expression and prognostic
significance of retinoic acid metabolising enzymes in colorectal
cancer. PLoS One. 9:e907762014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Elliott BE, Maxwell L, Arnold M, Wei WZ
and Miller FR: Expression of epithelial-like markers and class I
major histo-compatibility antigens by a murine carcinoma growing in
the mammary gland and in metastases: Orthotopic site effects.
Cancer Res. 48:7237–7245. 1988.PubMed/NCBI
|
|
15
|
Dimri GP, Lee X, Basile G, Acosta M, Scott
G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O,
et al: A biomarker that identifies senescent human cells in culture
and in aging skin in vivo. Proc Natl Acad Sci USA. 92:9363–9367.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Murray GI, Patimalla S, Stewart KN, Miller
ID and Heys SD: Profiling the expression of cytochrome P450 in
breast cancer. Histopathology. 57:202–211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ben-Porath I and Weinberg RA: When cells
get stressed: An integrative view of cellular senescence. J Clin
Invest. 113:8–13. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kawasaki H, Eckner R, Yao TP, Taira K,
Chiu R, Livingston DM and Yokoyama KK: Distinct roles of the
co-activators p300 and CBP in retinoic-acid-induced F9-cell
differentiation. Nature. 393:284–289. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Megiorni F, Indovina P, Mora B and
Mazzilli MC: Minor expression of fascin-1 gene (FSCN1) in NTera2
cells depleted of CREB-binding protein. Neurosci Lett. 381:169–174.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McConnell BB, Starborg M, Brookes S and
Peters G: Inhibitors of cyclin-dependent kinases induce features of
replicative senescence in early passage human diploid fibroblasts.
Curr Biol. 8:351–354. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Trost TM, Lausch EU, Fees SA, Schmitt S,
Enklaar T, Reutzel D, Brixel LR, Schmidtke P, Maringer M, Schiffer
IB, et al: Premature senescence is a primary fail-safe mechanism of
ERBB2-driven tumorigenesis in breast carcinoma cells. Cancer Res.
65:840–849. 2005.PubMed/NCBI
|
|
22
|
te Poele RH, Okorokov AL, Jardine L,
Cummings J and Joel SP: DNA damage is able to induce senescence in
tumor cells in vitro and in vivo. Cancer Res. 62:1876–1883.
2002.PubMed/NCBI
|
|
23
|
Sherr CJ and DePinho RA: Cellular
senescence: Mitotic clock or culture shock? Cell. 102:407–410.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chang BD, Broude EV, Dokmanovic M, Zhu H,
Ruth A, Xuan Y, Kandel ES, Lausch E, Christov K and Roninson IB: A
senescence-like phenotype distinguishes tumor cells that undergo
terminal proliferation arrest after exposure to anticancer agents.
Cancer Res. 59:3761–3767. 1999.PubMed/NCBI
|
